Equity Profile

CLDX

Celldex Therapeutics, Inc.

Health CareBiotechnology$2.5B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative immunotherapies for cancer and other serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CLDX Q2-2026 Earnings Preview

Context

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative immunotherapies for cancer and other serious diseases. With a market cap of $2 billion, its work is significant in the healthcare sector, particularly as the demand for advanced treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.75%

Avg Stock Reaction

+3.90%

Last Quarter Recap

In Q1-2026, Celldex reported an EPS of -$1.18, missing estimates by 6.88%. The stock reacted negatively, dropping 3.11% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's recent history of missing EPS estimates. The upcoming report is crucial for assessing future growth potential.

Bull Case

If Celldex can demonstrate improved financial metrics and positive developments in its pipeline, it could regain investor confidence and see a significant stock price increase.

Bear Case

Continued losses and missed expectations could lead to further declines in stock price, especially if the company fails to provide a clear path to profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected timeline for key product developments?

Understanding the timeline for product advancements will help gauge the company's future revenue potential and market positioning.

How does management plan to address the recent EPS misses?

Insight into management's strategy for improving financial performance is critical for investor confidence and stock stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Celldex's pipeline to deliver unexpected positive results, leading to a stronger than anticipated performance.

Supporting Evidence

Options pricing suggests a larger move than historical averages, indicating potential for significant surprises.

The recent drop in stock price may have already priced in a worst-case scenario, leaving room for upside.

Historical patterns show that the stock has rebounded after previous misses, suggesting resilience.

Key Risk

If the company can show progress in its product pipeline, it could significantly alter the negative sentiment currently prevailing in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Celldex can turn around its financial performance amidst ongoing development challenges.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would indicate a positive trend in financial performance.

Bear Confirmed If

An EPS loss greater than -$1.20 would reinforce negative sentiment and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±22.49%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±23.6% while CLDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.3%

Calls (1K)P/C Ratio: 1.00Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celldex beats expectations, history suggests a potential stock increase of around 2.01%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline of about 5.80%, reflecting ongoing concerns about the company’s financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key drug candidates in the pipeline.
2Any changes to financial guidance or expectations for the upcoming quarters.
3Management's commentary on strategies to address recent EPS misses.
4Insights into market conditions and competitive landscape affecting product adoption.
5Details on partnerships or collaborations that could enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative immunotherapies for cancer and other serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CLDX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.75%

Avg Stock Reaction

+3.90%

Last Quarter Recap

In Q1-2026, Celldex reported an EPS of -$1.18, missing estimates by 6.88%. The stock reacted negatively, dropping 3.11% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's recent history of missing EPS estimates. The upcoming report is crucial for assessing future growth potential.

Bull Case

If Celldex can demonstrate improved financial metrics and positive developments in its pipeline, it could regain investor confidence and see a significant stock price increase.

Bear Case

Continued losses and missed expectations could lead to further declines in stock price, especially if the company fails to provide a clear path to profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the projected timeline for key product developments?

Understanding the timeline for product advancements will help gauge the company's future revenue potential and market positioning.

How does management plan to address the recent EPS misses?

Insight into management's strategy for improving financial performance is critical for investor confidence and stock stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Celldex's pipeline to deliver unexpected positive results, leading to a stronger than anticipated performance.

Supporting Evidence

Options pricing suggests a larger move than historical averages, indicating potential for significant surprises.

The recent drop in stock price may have already priced in a worst-case scenario, leaving room for upside.

Historical patterns show that the stock has rebounded after previous misses, suggesting resilience.

Key Risk

If the company can show progress in its product pipeline, it could significantly alter the negative sentiment currently prevailing in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Celldex can turn around its financial performance amidst ongoing development challenges.

Bull Confirmed If

A reduction in EPS losses to below -$1.00 would indicate a positive trend in financial performance.

Bear Confirmed If

An EPS loss greater than -$1.20 would reinforce negative sentiment and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±22.49%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±23.6% while CLDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.3%

Calls (1K)P/C Ratio: 1.00Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celldex beats expectations, history suggests a potential stock increase of around 2.01%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline of about 5.80%, reflecting ongoing concerns about the company’s financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key drug candidates in the pipeline.
2Any changes to financial guidance or expectations for the upcoming quarters.
3Management's commentary on strategies to address recent EPS misses.
4Insights into market conditions and competitive landscape affecting product adoption.
5Details on partnerships or collaborations that could enhance growth prospects.